APO Research
Talk to an analyst

APO RESEARCH · REPORT

Antihemophilic Factor & von Willebrand Factor Complex

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Antihemophilic Factor & von Willebrand Factor Complex Market Outlook and Growth Opportunities 2026

2 January 2026193 pages

Choose your research edition.

Industry ResearchAntihemophilic Factor & von Willebrand Factor Complex Industry Research Report 2026105 pages · $2,950 USDIndustry Growth & TrendsGlobal Antihemophilic Factor & von Willebrand Factor Complex Industry Growth and Trends Forecast to 203261 pages · $3,450 USDMarket StructureGlobal Antihemophilic Factor & von Willebrand Factor Complex Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032175 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Antihemophilic Factor & von Willebrand Factor Complex Market Outlook and Growth Opportunities 2026193 pages · $4,250 USDMarket Analysis & ForecastGlobal Antihemophilic Factor & von Willebrand Factor Complex Market Analysis and Forecast 2026-2032195 pages · $4,950 USD

Market perspective

The global Antihemophilic Factor & von Willebrand Factor Complex market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Antihemophilic Factor & von Willebrand Factor Complex is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Antihemophilic Factor & von Willebrand Factor Complex is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Antihemophilic Factor & von Willebrand Factor Complex is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Antihemophilic Factor & von Willebrand Factor Complex market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Antihemophilic Factor & von Willebrand Factor Complex market include Takeda, Octapharma, Grifols and CSL Behring, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global Antihemophilic Factor & von Willebrand Factor Complex market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Antihemophilic Factor & von Willebrand Factor Complex and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Antihemophilic Factor & von Willebrand Factor Complex revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Antihemophilic Factor & von Willebrand Factor Complex market.

Antihemophilic Factor & von Willebrand Factor Complex Segment by Company

Takeda

Octapharma

Grifols

CSL Behring

Antihemophilic Factor & von Willebrand Factor Complex Segment by Type

10 ml

15 ml

5 ml

Antihemophilic Factor & von Willebrand Factor Complex Segment by Application

Hospital

Clinic

Antihemophilic Factor & von Willebrand Factor Complex Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global Antihemophilic Factor & von Willebrand Factor Complex status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Antihemophilic Factor & von Willebrand Factor Complex key companies, revenue, market share, and recent developments.

3. To split the Antihemophilic Factor & von Willebrand Factor Complex breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Antihemophilic Factor & von Willebrand Factor Complex market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Antihemophilic Factor & von Willebrand Factor Complex significant trends, drivers, influence factors in global and regions.

6. To analyze Antihemophilic Factor & von Willebrand Factor Complex competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Antihemophilic Factor & von Willebrand Factor Complex market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Antihemophilic Factor & von Willebrand Factor Complex and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Antihemophilic Factor & von Willebrand Factor Complex.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Antihemophilic Factor & von Willebrand Factor Complex industry.

Chapter 3: Detailed analysis of Antihemophilic Factor & von Willebrand Factor Complex company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Antihemophilic Factor & von Willebrand Factor Complex in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Antihemophilic Factor & von Willebrand Factor Complex in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Antihemophilic Factor & von Willebrand Factor Complex Industry Trends Table 2. Antihemophilic Factor & von Willebrand Factor Complex Industry Drivers Table 3. Antihemophilic Factor & von Willebrand Factor Complex Industry Opportunities and Challenges Table 4. Antihemophilic Factor & von Willebrand Factor Complex Industry Restraints Table 5. Global Antihemophilic Factor & von Willebrand Factor Complex Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Antihemophilic Factor & von Willebrand Factor Complex Revenue Share by Company (2021-2026) Table 7. Global Antihemophilic Factor & von Willebrand Factor Complex Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Antihemophilic Factor & von Willebrand Factor Complex Key Company Manufacturing Base & Headquarters Table 9. Global Antihemophilic Factor & von Willebrand Factor Complex Company, Product Type & Application Table 10. Global Antihemophilic Factor & von Willebrand Factor Complex Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Antihemophilic Factor & von Willebrand Factor Complex by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of 10 ml Table 15. Significant Companies of 15 ml Table 16. Significant Companies of 5 ml Table 17. Global Antihemophilic Factor & von Willebrand Factor Complex Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 18. Global Antihemophilic Factor & von Willebrand Factor Complex Sales Value by Type (2021-2026) & (US$ Million) Table 19. Global Antihemophilic Factor & von Willebrand Factor Complex Sales Value by Type (2027-2032) & (US$ Million) Table 20. Global Antihemophilic Factor & von Willebrand Factor Complex Sales Value Share by Type (2021-2026) Table 21. Global Antihemophilic Factor & von Willebrand Factor Complex Sales Value Share by Type (2027-2032) Table 22. Significant Companies of Hospital Table 23. Significant Companies of Clinic Table 24. Global Antihemophilic Factor & von Willebrand Factor Complex Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 25. Global Antihemophilic Factor & von Willebrand Factor Complex Sales Value by Application (2021-2026) & (US$ Million) Table 26. Global Antihemophilic Factor & von Willebrand Factor Complex Sales Value by Application (2027-2032) & (US$ Million) Table 27. Global Antihemophilic Factor & von Willebrand Factor Complex Sales Value Share by Application (2021-2026) Table 28. Global Antihemophilic Factor & von Willebrand Factor Complex Sales Value Share by Application (2027-2032) Table 29. Global Antihemophilic Factor & von Willebrand Factor Complex Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 30. Global Antihemophilic Factor & von Willebrand Factor Complex Sales Value by Region (2021-2026) & (US$ Million) Table 31. Global Antihemophilic Factor & von Willebrand Factor Complex Sales Value Share by Region (2021-2026) Table 32. Global Antihemophilic Factor & von Willebrand Factor Complex Sales Value by Region (2027-2032) & (US$ Million) Table 33. Global Antihemophilic Factor & von Willebrand Factor Complex Sales Value Share by Region (2027-2032) Table 34. Global Antihemophilic Factor & von Willebrand Factor Complex Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 35. Global Antihemophilic Factor & von Willebrand Factor Complex Sales Value by Country (2021-2026) & (US$ Million) Table 36. Global Antihemophilic Factor & von Willebrand Factor Complex Sales Value Market Share by Country (2021-2026) Table 37. Global Antihemophilic Factor & von Willebrand Factor Complex Sales Value by Country (2027-2032) & (US$ Million) Table 38. Global Antihemophilic Factor & von Willebrand Factor Complex Sales Value Market Share by Country (2027-2032) Table 39. Takeda Company Information Table 40. Takeda Business Overview Table 41. Takeda Antihemophilic Factor & von Willebrand Factor Complex Revenue (US$ Million) and Gross Margin (2021-2026) Table 42. Takeda Antihemophilic Factor & von Willebrand Factor Complex Product Portfolio Table 43. Takeda Recent Development Table 44. Octapharma Company Information Table 45. Octapharma Business Overview Table 46. Octapharma Antihemophilic Factor & von Willebrand Factor Complex Revenue (US$ Million) and Gross Margin (2021-2026) Table 47. Octapharma Antihemophilic Factor & von Willebrand Factor Complex Product Portfolio Table 48. Octapharma Recent Development Table 49. Grifols Company Information Table 50. Grifols Business Overview Table 51. Grifols Antihemophilic Factor & von Willebrand Factor Complex Revenue (US$ Million) and Gross Margin (2021-2026) Table 52. Grifols Antihemophilic Factor & von Willebrand Factor Complex Product Portfolio Table 53. Grifols Recent Development Table 54. CSL Behring Company Information Table 55. CSL Behring Business Overview Table 56. CSL Behring Antihemophilic Factor & von Willebrand Factor Complex Revenue (US$ Million) and Gross Margin (2021-2026) Table 57. CSL Behring Antihemophilic Factor & von Willebrand Factor Complex Product Portfolio Table 58. CSL Behring Recent Development Table 59. Research Programs/Design for This Report Table 60. Authors List of This Report Table 61. Secondary Sources Table 62. Primary Sources List of Figures Figure 1. Antihemophilic Factor & von Willebrand Factor Complex Product Image Figure 2. Global Antihemophilic Factor & von Willebrand Factor Complex Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Antihemophilic Factor & von Willebrand Factor Complex Market Size (2021-2032) & (US$ Million) Figure 4. Global Antihemophilic Factor & von Willebrand Factor Complex Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. 10 ml Image Figure 8. 15 ml Image Figure 9. 5 ml Image Figure 10. Global Antihemophilic Factor & von Willebrand Factor Complex Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 11. Global Antihemophilic Factor & von Willebrand Factor Complex Sales Value Share 2021 VS 2025 VS 2032 Figure 12. Global Antihemophilic Factor & von Willebrand Factor Complex Sales Value Share by Type (2021-2032) Figure 13. Hospital Image Figure 14. Clinic Image Figure 15. Global Antihemophilic Factor & von Willebrand Factor Complex Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 16. Global Antihemophilic Factor & von Willebrand Factor Complex Sales Value Share 2021 VS 2025 VS 2032 Figure 17. Global Antihemophilic Factor & von Willebrand Factor Complex Sales Value Share by Application (2021-2032) Figure 18. Global Antihemophilic Factor & von Willebrand Factor Complex Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 19. Global Antihemophilic Factor & von Willebrand Factor Complex Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 20. North America Antihemophilic Factor & von Willebrand Factor Complex Sales Value (2021-2032) & (US$ Million) Figure 21. North America Antihemophilic Factor & von Willebrand Factor Complex Sales Value Share by Country (%), 2025 VS 2032 Figure 22. Europe Antihemophilic Factor & von Willebrand Factor Complex Sales Value (2021-2032) & (US$ Million) Figure 23. Europe Antihemophilic Factor & von Willebrand Factor Complex Sales Value Share by Country (%), 2025 VS 2032 Figure 24. Asia-Pacific Antihemophilic Factor & von Willebrand Factor Complex Sales Value (2021-2032) & (US$ Million) Figure 25. Asia-Pacific Antihemophilic Factor & von Willebrand Factor Complex Sales Value Share by Country (%), 2025 VS 2032 Figure 26. South America Antihemophilic Factor & von Willebrand Factor Complex Sales Value (2021-2032) & (US$ Million) Figure 27. South America Antihemophilic Factor & von Willebrand Factor Complex Sales Value Share by Country (%), 2025 VS 2032 Figure 28. Middle East & Africa Antihemophilic Factor & von Willebrand Factor Complex Sales Value (2021-2032) & (US$ Million) Figure 29. Middle East & Africa Antihemophilic Factor & von Willebrand Factor Complex Sales Value Share by Country (%), 2025 VS 2032 Figure 30. USA Antihemophilic Factor & von Willebrand Factor Complex Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 31. USA Antihemophilic Factor & von Willebrand Factor Complex Sales Value Share by Type, 2025 VS 2032 & (%) Figure 32. USA Antihemophilic Factor & von Willebrand Factor Complex Sales Value Share by Application, 2025 VS 2032 & (%) Figure 33. Canada Antihemophilic Factor & von Willebrand Factor Complex Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 34. Canada Antihemophilic Factor & von Willebrand Factor Complex Sales Value Share by Type, 2025 VS 2032 & (%) Figure 35. Canada Antihemophilic Factor & von Willebrand Factor Complex Sales Value Share by Application, 2025 VS 2032 & (%) Figure 36. Mexico Antihemophilic Factor & von Willebrand Factor Complex Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 37. Mexico Antihemophilic Factor & von Willebrand Factor Complex Sales Value Share by Type, 2025 VS 2032 & (%) Figure 38. Mexico Antihemophilic Factor & von Willebrand Factor Complex Sales Value Share by Application, 2025 VS 2032 & (%) Figure 39. Germany Antihemophilic Factor & von Willebrand Factor Complex Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 40. Germany Antihemophilic Factor & von Willebrand Factor Complex Sales Value Share by Type, 2025 VS 2032 & (%) Figure 41. Germany Antihemophilic Factor & von Willebrand Factor Complex Sales Value Share by Application, 2025 VS 2032 & (%) Figure 42. France Antihemophilic Factor & von Willebrand Factor Complex Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 43. France Antihemophilic Factor & von Willebrand Factor Complex Sales Value Share by Type, 2025 VS 2032 & (%) Figure 44. France Antihemophilic Factor & von Willebrand Factor Complex Sales Value Share by Application, 2025 VS 2032 & (%) Figure 45. U.K. Antihemophilic Factor & von Willebrand Factor Complex Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. U.K. Antihemophilic Factor & von Willebrand Factor Complex Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. U.K. Antihemophilic Factor & von Willebrand Factor Complex Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. Italy Antihemophilic Factor & von Willebrand Factor Complex Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. Italy Antihemophilic Factor & von Willebrand Factor Complex Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. Italy Antihemophilic Factor & von Willebrand Factor Complex Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. Spain Antihemophilic Factor & von Willebrand Factor Complex Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. Spain Antihemophilic Factor & von Willebrand Factor Complex Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. Spain Antihemophilic Factor & von Willebrand Factor Complex Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. Russia Antihemophilic Factor & von Willebrand Factor Complex Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. Russia Antihemophilic Factor & von Willebrand Factor Complex Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. Russia Antihemophilic Factor & von Willebrand Factor Complex Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. Netherlands Antihemophilic Factor & von Willebrand Factor Complex Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. Netherlands Antihemophilic Factor & von Willebrand Factor Complex Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. Netherlands Antihemophilic Factor & von Willebrand Factor Complex Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. Nordic Countries Antihemophilic Factor & von Willebrand Factor Complex Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. Nordic Countries Antihemophilic Factor & von Willebrand Factor Complex Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. Nordic Countries Antihemophilic Factor & von Willebrand Factor Complex Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. China Antihemophilic Factor & von Willebrand Factor Complex Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. China Antihemophilic Factor & von Willebrand Factor Complex Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. China Antihemophilic Factor & von Willebrand Factor Complex Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. Japan Antihemophilic Factor & von Willebrand Factor Complex Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. Japan Antihemophilic Factor & von Willebrand Factor Complex Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. Japan Antihemophilic Factor & von Willebrand Factor Complex Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. South Korea Antihemophilic Factor & von Willebrand Factor Complex Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. South Korea Antihemophilic Factor & von Willebrand Factor Complex Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. South Korea Antihemophilic Factor & von Willebrand Factor Complex Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. India Antihemophilic Factor & von Willebrand Factor Complex Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. India Antihemophilic Factor & von Willebrand Factor Complex Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. India Antihemophilic Factor & von Willebrand Factor Complex Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. Australia Antihemophilic Factor & von Willebrand Factor Complex Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. Australia Antihemophilic Factor & von Willebrand Factor Complex Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. Australia Antihemophilic Factor & von Willebrand Factor Complex Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. Southeast Asia Antihemophilic Factor & von Willebrand Factor Complex Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. Southeast Asia Antihemophilic Factor & von Willebrand Factor Complex Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. Southeast Asia Antihemophilic Factor & von Willebrand Factor Complex Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. Brazil Antihemophilic Factor & von Willebrand Factor Complex Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. Brazil Antihemophilic Factor & von Willebrand Factor Complex Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. Brazil Antihemophilic Factor & von Willebrand Factor Complex Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. Argentina Antihemophilic Factor & von Willebrand Factor Complex Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. Argentina Antihemophilic Factor & von Willebrand Factor Complex Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. Argentina Antihemophilic Factor & von Willebrand Factor Complex Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. Chile Antihemophilic Factor & von Willebrand Factor Complex Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. Chile Antihemophilic Factor & von Willebrand Factor Complex Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. Chile Antihemophilic Factor & von Willebrand Factor Complex Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Colombia Antihemophilic Factor & von Willebrand Factor Complex Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Colombia Antihemophilic Factor & von Willebrand Factor Complex Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Colombia Antihemophilic Factor & von Willebrand Factor Complex Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Peru Antihemophilic Factor & von Willebrand Factor Complex Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Peru Antihemophilic Factor & von Willebrand Factor Complex Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Peru Antihemophilic Factor & von Willebrand Factor Complex Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Saudi Arabia Antihemophilic Factor & von Willebrand Factor Complex Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Saudi Arabia Antihemophilic Factor & von Willebrand Factor Complex Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Saudi Arabia Antihemophilic Factor & von Willebrand Factor Complex Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Israel Antihemophilic Factor & von Willebrand Factor Complex Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Israel Antihemophilic Factor & von Willebrand Factor Complex Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Israel Antihemophilic Factor & von Willebrand Factor Complex Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. UAE Antihemophilic Factor & von Willebrand Factor Complex Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. UAE Antihemophilic Factor & von Willebrand Factor Complex Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. UAE Antihemophilic Factor & von Willebrand Factor Complex Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. Turkey Antihemophilic Factor & von Willebrand Factor Complex Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. Turkey Antihemophilic Factor & von Willebrand Factor Complex Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. Turkey Antihemophilic Factor & von Willebrand Factor Complex Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Iran Antihemophilic Factor & von Willebrand Factor Complex Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Iran Antihemophilic Factor & von Willebrand Factor Complex Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Iran Antihemophilic Factor & von Willebrand Factor Complex Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. Egypt Antihemophilic Factor & von Willebrand Factor Complex Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. Egypt Antihemophilic Factor & von Willebrand Factor Complex Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. Egypt Antihemophilic Factor & von Willebrand Factor Complex Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. Years Considered Figure 115. Research Process Figure 116. Key Executives Interviewed

Scope & coverage.

Types
  • 10 ml
  • 15 ml
  • 5 ml
Applications
  • Hospital
  • Clinic
Companies covered
  • Takeda
  • Octapharma
  • Grifols
  • CSL Behring

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Antihemophilic Factor & von Willebrand Factor Complex Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Antihemophilic Factor & von Willebrand Factor Complex Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Antihemophilic Factor & von Willebrand Factor Complex Market Dynamics
  1. 2.1 Antihemophilic Factor & von Willebrand Factor Complex Industry Trends
  2. 2.2 Antihemophilic Factor & von Willebrand Factor Complex Industry Drivers
  3. 2.3 Antihemophilic Factor & von Willebrand Factor Complex Industry Opportunities and Challenges
  4. 2.4 Antihemophilic Factor & von Willebrand Factor Complex Industry Restraints
3 Antihemophilic Factor & von Willebrand Factor Complex Market by Company
  1. 3.1 Global Antihemophilic Factor & von Willebrand Factor Complex Company Revenue Ranking in 2025
  2. 3.2 Global Antihemophilic Factor & von Willebrand Factor Complex Revenue by Company (2021-2026)
  3. 3.3 Global Antihemophilic Factor & von Willebrand Factor Complex Company Ranking (2024-2026)
  4. 3.4 Global Antihemophilic Factor & von Willebrand Factor Complex Company Manufacturing Base and Headquarters
  5. 3.5 Global Antihemophilic Factor & von Willebrand Factor Complex Company Product Type and Application
  6. 3.6 Global Antihemophilic Factor & von Willebrand Factor Complex Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Antihemophilic Factor & von Willebrand Factor Complex Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Antihemophilic Factor & von Willebrand Factor Complex Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Antihemophilic Factor & von Willebrand Factor Complex Market by Type
  1. 4.1 Antihemophilic Factor & von Willebrand Factor Complex Type Introduction
  2. 4.1.1 10 ml
  3. 4.1.2 15 ml
  4. 4.1.3 5 ml
  5. 4.2 Global Antihemophilic Factor & von Willebrand Factor Complex Sales Value by Type
  6. 4.2.1 Global Antihemophilic Factor & von Willebrand Factor Complex Sales Value by Type (2021 VS 2025 VS 2032)
  7. 4.2.2 Global Antihemophilic Factor & von Willebrand Factor Complex Sales Value by Type (2021-2032)
  8. 4.2.3 Global Antihemophilic Factor & von Willebrand Factor Complex Sales Value Share by Type (2021-2032)
5 Antihemophilic Factor & von Willebrand Factor Complex Market by Application
  1. 5.1 Antihemophilic Factor & von Willebrand Factor Complex Application Introduction
  2. 5.1.1 Hospital
  3. 5.1.2 Clinic
  4. 5.2 Global Antihemophilic Factor & von Willebrand Factor Complex Sales Value by Application
  5. 5.2.1 Global Antihemophilic Factor & von Willebrand Factor Complex Sales Value by Application (2021 VS 2025 VS 2032)
  6. 5.2.2 Global Antihemophilic Factor & von Willebrand Factor Complex Sales Value by Application (2021-2032)
  7. 5.2.3 Global Antihemophilic Factor & von Willebrand Factor Complex Sales Value Share by Application (2021-2032)
6 Antihemophilic Factor & von Willebrand Factor Complex Regional Value Analysis
  1. 6.1 Global Antihemophilic Factor & von Willebrand Factor Complex Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Antihemophilic Factor & von Willebrand Factor Complex Sales Value by Region (2021-2032)
  3. 6.2.1 Global Antihemophilic Factor & von Willebrand Factor Complex Sales Value by Region: 2021-2026
  4. 6.2.2 Global Antihemophilic Factor & von Willebrand Factor Complex Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Antihemophilic Factor & von Willebrand Factor Complex Sales Value (2021-2032)
  7. 6.3.2 North America Antihemophilic Factor & von Willebrand Factor Complex Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Antihemophilic Factor & von Willebrand Factor Complex Sales Value (2021-2032)
  10. 6.4.2 Europe Antihemophilic Factor & von Willebrand Factor Complex Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Antihemophilic Factor & von Willebrand Factor Complex Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Antihemophilic Factor & von Willebrand Factor Complex Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Antihemophilic Factor & von Willebrand Factor Complex Sales Value (2021-2032)
  16. 6.6.2 South America Antihemophilic Factor & von Willebrand Factor Complex Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Antihemophilic Factor & von Willebrand Factor Complex Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Antihemophilic Factor & von Willebrand Factor Complex Sales Value Share by Country, 2025 VS 2032
7 Antihemophilic Factor & von Willebrand Factor Complex Country-level Value Analysis
  1. 7.1 Global Antihemophilic Factor & von Willebrand Factor Complex Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Antihemophilic Factor & von Willebrand Factor Complex Sales Value by Country (2021-2032)
  3. 7.2.1 Global Antihemophilic Factor & von Willebrand Factor Complex Sales Value by Country (2021-2026)
  4. 7.2.2 Global Antihemophilic Factor & von Willebrand Factor Complex Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Antihemophilic Factor & von Willebrand Factor Complex Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Antihemophilic Factor & von Willebrand Factor Complex Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Antihemophilic Factor & von Willebrand Factor Complex Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Antihemophilic Factor & von Willebrand Factor Complex Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Antihemophilic Factor & von Willebrand Factor Complex Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Antihemophilic Factor & von Willebrand Factor Complex Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Antihemophilic Factor & von Willebrand Factor Complex Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Antihemophilic Factor & von Willebrand Factor Complex Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Antihemophilic Factor & von Willebrand Factor Complex Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Antihemophilic Factor & von Willebrand Factor Complex Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Antihemophilic Factor & von Willebrand Factor Complex Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Antihemophilic Factor & von Willebrand Factor Complex Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Antihemophilic Factor & von Willebrand Factor Complex Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Antihemophilic Factor & von Willebrand Factor Complex Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Antihemophilic Factor & von Willebrand Factor Complex Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Antihemophilic Factor & von Willebrand Factor Complex Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Antihemophilic Factor & von Willebrand Factor Complex Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Antihemophilic Factor & von Willebrand Factor Complex Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Antihemophilic Factor & von Willebrand Factor Complex Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Antihemophilic Factor & von Willebrand Factor Complex Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Antihemophilic Factor & von Willebrand Factor Complex Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Antihemophilic Factor & von Willebrand Factor Complex Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Antihemophilic Factor & von Willebrand Factor Complex Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Antihemophilic Factor & von Willebrand Factor Complex Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Antihemophilic Factor & von Willebrand Factor Complex Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Antihemophilic Factor & von Willebrand Factor Complex Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Antihemophilic Factor & von Willebrand Factor Complex Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Antihemophilic Factor & von Willebrand Factor Complex Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Antihemophilic Factor & von Willebrand Factor Complex Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Antihemophilic Factor & von Willebrand Factor Complex Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Antihemophilic Factor & von Willebrand Factor Complex Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Antihemophilic Factor & von Willebrand Factor Complex Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Antihemophilic Factor & von Willebrand Factor Complex Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Antihemophilic Factor & von Willebrand Factor Complex Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Antihemophilic Factor & von Willebrand Factor Complex Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Antihemophilic Factor & von Willebrand Factor Complex Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Antihemophilic Factor & von Willebrand Factor Complex Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Antihemophilic Factor & von Willebrand Factor Complex Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Antihemophilic Factor & von Willebrand Factor Complex Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Antihemophilic Factor & von Willebrand Factor Complex Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Antihemophilic Factor & von Willebrand Factor Complex Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Antihemophilic Factor & von Willebrand Factor Complex Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Antihemophilic Factor & von Willebrand Factor Complex Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Antihemophilic Factor & von Willebrand Factor Complex Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Antihemophilic Factor & von Willebrand Factor Complex Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Antihemophilic Factor & von Willebrand Factor Complex Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Antihemophilic Factor & von Willebrand Factor Complex Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Antihemophilic Factor & von Willebrand Factor Complex Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Antihemophilic Factor & von Willebrand Factor Complex Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Antihemophilic Factor & von Willebrand Factor Complex Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Antihemophilic Factor & von Willebrand Factor Complex Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Antihemophilic Factor & von Willebrand Factor Complex Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Antihemophilic Factor & von Willebrand Factor Complex Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Antihemophilic Factor & von Willebrand Factor Complex Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Antihemophilic Factor & von Willebrand Factor Complex Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Antihemophilic Factor & von Willebrand Factor Complex Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Antihemophilic Factor & von Willebrand Factor Complex Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Antihemophilic Factor & von Willebrand Factor Complex Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Antihemophilic Factor & von Willebrand Factor Complex Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Antihemophilic Factor & von Willebrand Factor Complex Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Antihemophilic Factor & von Willebrand Factor Complex Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Antihemophilic Factor & von Willebrand Factor Complex Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Antihemophilic Factor & von Willebrand Factor Complex Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Antihemophilic Factor & von Willebrand Factor Complex Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Antihemophilic Factor & von Willebrand Factor Complex Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Antihemophilic Factor & von Willebrand Factor Complex Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Antihemophilic Factor & von Willebrand Factor Complex Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Antihemophilic Factor & von Willebrand Factor Complex Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Antihemophilic Factor & von Willebrand Factor Complex Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Antihemophilic Factor & von Willebrand Factor Complex Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Antihemophilic Factor & von Willebrand Factor Complex Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Antihemophilic Factor & von Willebrand Factor Complex Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Antihemophilic Factor & von Willebrand Factor Complex Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Antihemophilic Factor & von Willebrand Factor Complex Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Antihemophilic Factor & von Willebrand Factor Complex Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Antihemophilic Factor & von Willebrand Factor Complex Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Antihemophilic Factor & von Willebrand Factor Complex Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Antihemophilic Factor & von Willebrand Factor Complex Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Antihemophilic Factor & von Willebrand Factor Complex Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Antihemophilic Factor & von Willebrand Factor Complex Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Antihemophilic Factor & von Willebrand Factor Complex Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Antihemophilic Factor & von Willebrand Factor Complex Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Antihemophilic Factor & von Willebrand Factor Complex Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Antihemophilic Factor & von Willebrand Factor Complex Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Takeda
  2. 8.1.1 Takeda Company Information
  3. 8.1.2 Takeda Business Overview
  4. 8.1.3 Takeda Antihemophilic Factor & von Willebrand Factor Complex Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Takeda Antihemophilic Factor & von Willebrand Factor Complex Product Portfolio
  6. 8.1.5 Takeda Recent Developments
  7. 8.2 Octapharma
  8. 8.2.1 Octapharma Company Information
  9. 8.2.2 Octapharma Business Overview
  10. 8.2.3 Octapharma Antihemophilic Factor & von Willebrand Factor Complex Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Octapharma Antihemophilic Factor & von Willebrand Factor Complex Product Portfolio
  12. 8.2.5 Octapharma Recent Developments
  13. 8.3 Grifols
  14. 8.3.1 Grifols Company Information
  15. 8.3.2 Grifols Business Overview
  16. 8.3.3 Grifols Antihemophilic Factor & von Willebrand Factor Complex Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Grifols Antihemophilic Factor & von Willebrand Factor Complex Product Portfolio
  18. 8.3.5 Grifols Recent Developments
  19. 8.4 CSL Behring
  20. 8.4.1 CSL Behring Company Information
  21. 8.4.2 CSL Behring Business Overview
  22. 8.4.3 CSL Behring Antihemophilic Factor & von Willebrand Factor Complex Revenue and Gross Margin (2021-2026)
  23. 8.4.4 CSL Behring Antihemophilic Factor & von Willebrand Factor Complex Product Portfolio
  24. 8.4.5 CSL Behring Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst